7 completed, 4 recruiting, 2 active not recruiting. 6 Phase 1, 4 Phase 2, 3 Phase 3.
By phase and status
Follow AZD6234: new trials by email Literature Review of AZD6234 trials Research Report on AZD6234
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus Lenbelintide, Placebo - Obesity or Overweight, Weight-Related Comorbidity Phase 3 Recruiting 500 2026-08-24 2026-09-25 A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight Lenbelintide, Placebo - Obesity or Overweight, Diabetes Mellitus, Type 2 Phase 3 Recruiting 1500 2026-08-20 2026-10-28 A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus Lenbelintide, Placebo - Obesity or Overweight Phase 3 Recruiting 2500 2026-08-19 2026-10-30 A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234 AZD6234, AZD9550 - Hepatic Impairment Phase 1 Recruiting 28 2026-03-20 2026-10-22 A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234 AZD6234 Formulation 1, AZD6234 Formulation 2 (low concentration), AZD6234 Formulation 2 (high concentration) - Healthy Participants Phase 1 Completed 19 2025-11-11 2026-10-15 A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO), Acetaminophen (APAP) - Healthy Participants Phase 1 Active not recruiting 100 2025-06-04 2026-10-13 This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight AZD6234, Placebo, AZD9550 - Obesity/Overweight Phase 2 Active not recruiting 16 2025-05-20 2026-09-29 Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist AZD6234, Placebo to match - Endocrinology, Diabetes, Type II Phase 2 Completed 69 2025-03-12 2026-09-24 Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234 AZD6234 - Renal Impairment Phase 1 Completed 24 2025-02-24 2025-11-03 A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone AZD9550, AZD6234, Placebo comparator - Obesity or Overweight Phase 2 Completed 377 2025-02-18 2026-06-03 A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity AZD6234, Placebo comparator - Obesity or Overweight Phase 2 Completed 262 2024-10-01 2026-10-02 A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese AZD6234, Placebo - Healthy Participants Phase 1 Completed 104 2023-11-13 2026-04-03 Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese AZD6234, Placebo, Acetaminophen - Healthy Participants Phase 1 Completed 54 2022-09-20 2023-12-26
Conditions studied Obesity (11) · Overweight (10) · Diabetes Mellitus, Type 2 (3) · Lymphoma, Follicular (1) · Renal Insufficiency (1)
Sponsors AstraZeneca (13)
Countries United States (11) · Japan (6) · Canada (5) · Australia (4) · China (4) · United Kingdom (4) · Argentina (3) · Germany (3) · Brazil (2) · India (2) · Poland (2) · South Korea (2) · Taiwan (2) · Bulgaria (1) · Chile (1)
Top investigators Fadi Saba, M.D. (1) · Joel M Neutel, M.D. (1) · Kwabena Ayesu, M.D. (1) · Thomas C Marbury, M.D. (1)
NIH funding 2025 (3)